We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Harpoon Therapeutics Inc. (HARP) rose nearly 7% on Thursday after the immunotherapy company expanded its work with AbbVie Inc. (ABBV).
Harpoon said it signed a license and option agreement with AbbVie for its HPN217 drug candidate, and the companies agreed to expand their existing discovery collaboration to include up to six additional targets.
The expanded deal, which includes $50 million upfront and an additional $50 million when the first patient is dosed with HPN217, carries milestone payments potentially worth hundreds of millions of dollars to Harpoon.
Analysts at SVB Leerink reiterated their "outperform" rating on Harpoon shares and raised their price target to $28 from $24, saying the expanded deal with AbbVie further validates Harpoon's platform and extends its cash runway into the second half of 2022.
Harpoon shares were recently up 6.4%, to $15.39.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 21, 2019 12:20 ET (17:20 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
